Enhancing Pockels effect in strained silicon waveguides

© 2019 Optical Society of America. One print or electronic copy may be made for personal use only. Systematic reproduction and distribution, duplication of any material in this paper for a fee or for commercial purposes, or modifications of the content of this paper are prohibited"[EN] The magnitude and origin of the electro-optic measurements in strained silicon devices has been lately the object of a great controversy. Furthermore, recent works underline the importance of the masking effect of free carriers in strained waveguides and the low interaction between the mode and the highly strained areas. In the present work, the use of a p-i-n junction and an asymmetric cladding is proposed to eliminate the unwanted carrier influence and improve the electro-optical modulation response. The proposed configuration enhances the effective refractive index due to the strain-induced Pockels effect in more than two orders of magnitude with respect to the usual configuration. (C) 2019 Optical Society of America under the terms of the OSA Open Access Publishing AgreementMinisterio de Economía y Competitividad (MINECO/FEDER, UE) (TEC2016-76849); Universitat Politècnica de València (FPI-Irene Olivares); Ministerio de Educación, Cultura y Deporte (FPU17/04224); Generalitat Valenciana. Irene Olivares and Jorge Parra acknowledges the Universitat Politècnica de València and Generalitat Valenciana, respectively, for funding their research staff training (FPI) grant.Olivares-Sánchez-Mellado, I.; Parra Gómez, J.; Brimont, ACJ.; Sanchis Kilders, P. (2019). Enhancing Pockels effect in strained silicon waveguides. Optics Express. 27(19):26882-26892. https://doi.org/10.1364/OE.27.026882S26882268922719Komljenovic, T., Huang, D., Pintus, P., Tran, M. A., Davenport, M. L., & Bowers, J. E. (2018). Photonic Integrated Circuits Using Heterogeneous Integration on Silicon. Proceedings of the IEEE, 106(12), 2246-2257. doi:10.1109/jproc.2018.2864668He, M., Xu, M., Ren, Y., Jian, J., Ruan, Z., Xu, Y., … Cai, X. (2019). High-performance hybrid silicon and lithium niobate Mach–Zehnder modulators for 100 Gbit s−1 and beyond. Nature Photonics, 13(5), 359-364. doi:10.1038/s41566-019-0378-6Abel, S., Eltes, F., Ortmann, J. E., Messner, A., Castera, P., Wagner, T., … Fompeyrine, J. (2018). Large Pockels effect in micro- and nanostructured barium titanate integrated on silicon. Nature Materials, 18(1), 42-47. doi:10.1038/s41563-018-0208-0Haffner, C., Chelladurai, D., Fedoryshyn, Y., Josten, A., Baeuerle, B., Heni, W., … Leuthold, J. (2018). Low-loss plasmon-assisted electro-optic modulator. Nature, 556(7702), 483-486. doi:10.1038/s41586-018-0031-4Reed, G. T., Mashanovich, G., Gardes, F. Y., & Thomson, D. J. (2010). Silicon optical modulators. Nature Photonics, 4(8), 518-526. doi:10.1038/nphoton.2010.179Jacobsen, R. S., Andersen, K. N., Borel, P. I., Fage-Pedersen, J., Frandsen, L. H., Hansen, O., … Bjarklev, A. (2006). Strained silicon as a new electro-optic material. Nature, 441(7090), 199-202. doi:10.1038/nature04706Cazzanelli, M., & Schilling, J. (2016). Second order optical nonlinearity in silicon by symmetry breaking. Applied Physics Reviews, 3(1), 011104. doi:10.1063/1.4941558Manganelli, C. L., Pintus, P., & Bonati, C. (2015). Modeling of strain-induced Pockels effect in Silicon. Optics Express, 23(22), 28649. doi:10.1364/oe.23.028649Puckett, M. W., Smalley, J. S. T., Abashin, M., Grieco, A., & Fainman, Y. (2014). Tensor of the second-order nonlinear susceptibility in asymmetrically strained silicon waveguides: analysis and experimental validation. Optics Letters, 39(6), 1693. doi:10.1364/ol.39.001693Bianco, F., Fedus, K., Enrichi, F., Pierobon, R., Cazzanelli, M., Ghulinyan, M., … Pavesi, L. (2012). Two-dimensional micro-Raman mapping of stress and strain distributions in strained silicon waveguides. Semiconductor Science and Technology, 27(8), 085009. doi:10.1088/0268-1242/27/8/085009Chmielak, B., Matheisen, C., Ripperda, C., Bolten, J., Wahlbrink, T., Waldow, M., & Kurz, H. (2013). Investigation of local strain distribution and linear electro-optic effect in strained silicon waveguides. Optics Express, 21(21), 25324. doi:10.1364/oe.21.025324Schriever, C., Bianco, F., Cazzanelli, M., Ghulinyan, M., Eisenschmidt, C., de Boor, J., … Schilling, J. (2014). Second-Order Optical Nonlinearity in Silicon Waveguides: Inhomogeneous Stress and Interfaces. Advanced Optical Materials, 3(1), 129-136. doi:10.1002/adom.201400370Chmielak, B., Waldow, M., Matheisen, C., Ripperda, C., Bolten, J., Wahlbrink, T., … Kurz, H. (2011). Pockels effect based fully integrated, strained silicon electro-optic modulator. Optics Express, 19(18), 17212. doi:10.1364/oe.19.017212Damas, P., Le Roux, X., Le Bourdais, D., Cassan, E., Marris-Morini, D., Izard, N., … Vivien, L. (2014). Wavelength dependence of Pockels effect in strained silicon waveguides. Optics Express, 22(18), 22095. doi:10.1364/oe.22.022095Sharif Azadeh, S., Merget, F., Nezhad, M. P., & Witzens, J. (2015). On the measurement of the Pockels effect in strained silicon. Optics Letters, 40(8), 1877. doi:10.1364/ol.40.001877Borghi, M., Mancinelli, M., Merget, F., Witzens, J., Bernard, M., Ghulinyan, M., … Pavesi, L. (2015). High-frequency electro-optic measurement of strained silicon racetrack resonators. Optics Letters, 40(22), 5287. doi:10.1364/ol.40.005287Sharma, R., Puckett, M. W., Lin, H.-H., Isichenko, A., Vallini, F., & Fainman, Y. (2016). Effect of dielectric claddings on the electro-optic behavior of silicon waveguides. Optics Letters, 41(6), 1185. doi:10.1364/ol.41.001185Borghi, M., Mancinelli, M., Bernard, M., Ghulinyan, M., Pucker, G., & Pavesi, L. (2016). Homodyne Detection of Free Carrier Induced Electro-Optic Modulation in Strained Silicon Resonators. Journal of Lightwave Technology, 34(24), 5657-5668. doi:10.1109/jlt.2016.2628183Olivares, I., Angelova, T., & Sanchis, P. (2017). On the influence of interface charging dynamics and stressing conditions in strained silicon devices. Scientific Reports, 7(1). doi:10.1038/s41598-017-05067-9Khurgin, J. B., Stievater, T. H., Pruessner, M. W., & Rabinovich, W. S. (2015). On the origin of the second-order nonlinearity in strained Si–SiN structures. Journal of the Optical Society of America B, 32(12), 2494. doi:10.1364/josab.32.002494Damas, P., Marris-Morini, D., Cassan, E., & Vivien, L. (2016). Bond orbital description of the strain-induced second-order optical susceptibility in silicon. Physical Review B, 93(16). doi:10.1103/physrevb.93.165208Damas, P., Berciano, M., Marcaud, G., Alonso Ramos, C., Marris-Morini, D., Cassan, E., & Vivien, L. (2017). Comprehensive description of the electro-optic effects in strained silicon waveguides. Journal of Applied Physics, 122(15), 153105. doi:10.1063/1.4985836Avrutsky, I., & Soref, R. (2011). Phase-matched sum frequency generation in strained silicon waveguides using their second-order nonlinear optical susceptibility. Optics Express, 19(22), 21707. doi:10.1364/oe.19.021707Cazzanelli, M., Bianco, F., Borga, E., Pucker, G., Ghulinyan, M., Degoli, E., … Pavesi, L. (2011). Second-harmonic generation in silicon waveguides strained by silicon nitride. Nature Materials, 11(2), 148-154. doi:10.1038/nmat3200Castellan, C., Trenti, A., Vecchi, C., Marchesini, A., Mancinelli, M., Ghulinyan, M., … Pavesi, L. (2019). On the origin of second harmonic generation in silicon waveguides with silicon nitride cladding. Scientific Reports, 9(1). doi:10.1038/s41598-018-37660-xBerciano, M., Marcaud, G., Damas, P., Le Roux, X., Crozat, P., Alonso Ramos, C., … Vivien, L. (2018). Fast linear electro-optic effect in a centrosymmetric semiconductor. Communications Physics, 1(1). doi:10.1038/s42005-018-0064-xTimurdogan, E., Poulton, C. V., Byrd, M. J., & Watts, M. R. (2017). Electric field-induced second-order nonlinear optical effects in silicon waveguides. Nature Photonics, 11(3), 200-206. doi:10.1038/nphoton.2017.14Wortman, J. J., & Evans, R. A. (1965). Young’s Modulus, Shear Modulus, and Poisson’s Ratio in Silicon and Germanium. Journal of Applied Physics, 36(1), 153-156. doi:10.1063/1.1713863Hopcroft, M. A., Nix, W. D., & Kenny, T. W. (2010). What is the Young’s Modulus of Silicon? Journal of Microelectromechanical Systems, 19(2), 229-238. doi:10.1109/jmems.2009.203969

Refinement of the diagnostic approach for the identification of children and adolescents affected by familial hypercholesterolemia: Evidence from the LIPIGEN study

Background and aims: We aimed to describe the limitations of familiar hypercholesterolemia (FH) diagnosis in childhood based on the presence of the typical features of FH, such as physical sings of cholesterol accumulation and personal or family history of premature cardiovascular disease or hypercholesterolemia, comparing their prevalence in the adult and paediatric FH population, and to illustrate how additional information can lead to a more effective diagnosis of FH at a younger age.Methods: From the Italian LIPIGEN cohort, we selected 1188 (>= 18 years) and 708 (<18 years) genetically-confirmed heterozygous FH, with no missing personal FH features. The prevalence of personal and familial FH features was compared between the two groups. For a sub-group of the paediatric cohort (N = 374), data about premature coronary heart disease (CHD) in second-degree family members were also included in the evaluation.Results: The lower prevalence of typical FH features in children/adolescents vs adults was confirmed: the prevalence of tendon xanthoma was 2.1% vs 13.1%, and arcus cornealis was present in 1.6% vs 11.2% of the cohorts, respectively. No children presented clinical history of premature CHD or cerebral/peripheral vascular disease compared to 8.8% and 5.6% of adults, respectively. The prevalence of premature CHD in first-degree relatives was significantly higher in adults compared to children/adolescents (38.9% vs 19.7%). In the sub-cohort analysis, a premature CHD event in parents was reported in 63 out of 374 subjects (16.8%), but the percentage increased to 54.0% extending the evaluation also to second-degree relatives.Conclusions: In children, the typical FH features are clearly less informative than in adults. A more thorough data collection, adding information about second-degree relatives, could improve the diagnosis of FH at younger age

Twelve Variants Polygenic Score for Low-Density Lipoprotein Cholesterol Distribution in a Large Cohort of Patients With Clinically Diagnosed Familial Hypercholesterolemia With or Without Causative Mutations

: Background A significant proportion of individuals clinically diagnosed with familial hypercholesterolemia (FH), but without any disease-causing mutation, are likely to have polygenic hypercholesterolemia. We evaluated the distribution of a polygenic risk score, consisting of 12 low-density lipoprotein cholesterol (LDL-C)-raising variants (polygenic LDL-C risk score), in subjects with a clinical diagnosis of FH. Methods and Results Within the Lipid Transport Disorders Italian Genetic Network (LIPIGEN) study, 875 patients who were FH-mutation positive (women, 54.75%; mean age, 42.47±15.00 years) and 644 patients who were FH-mutation negative (women, 54.21%; mean age, 49.73±13.54 years) were evaluated. Patients who were FH-mutation negative had lower mean levels of pretreatment LDL-C than patients who were FH-mutation positive (217.14±55.49 versus 270.52±68.59 mg/dL, P<0.0001). The mean value (±SD) of the polygenic LDL-C risk score was 1.00 (±0.18) in patients who were FH-mutation negative and 0.94 (±0.20) in patients who were FH-mutation positive (P<0.0001). In the receiver operating characteristic analysis, the area under the curve for recognizing subjects characterized by polygenic hypercholesterolemia was 0.59 (95% CI, 0.56-0.62), with sensitivity and specificity being 78% and 36%, respectively, at 0.905 as a cutoff value. Higher mean polygenic LDL-C risk score levels were observed among patients who were FH-mutation negative having pretreatment LDL-C levels in the range of 150 to 350 mg/dL (150-249 mg/dL: 1.01 versus 0.91, P<0.0001; 250-349 mg/dL: 1.02 versus 0.95, P=0.0001). A positive correlation between polygenic LDL-C risk score and pretreatment LDL-C levels was observed among patients with FH independently of the presence of causative mutations. Conclusions This analysis confirms the role of polymorphisms in modulating LDL-C levels, even in patients with genetically confirmed FH. More data are needed to support the use of the polygenic score in routine clinical practice

Refinement of the diagnostic approach for the identification of children and adolescents affected by familial hypercholesterolemia: Evidence from the LIPIGEN study

Background and aims: We aimed to describe the limitations of familiar hypercholesterolemia (FH) diagnosis in childhood based on the presence of the typical features of FH, such as physical sings of cholesterol accumulation and personal or family history of premature cardiovascular disease or hypercholesterolemia, comparing their prevalence in the adult and paediatric FH population, and to illustrate how additional information can lead to a more effective diagnosis of FH at a younger age. Methods: From the Italian LIPIGEN cohort, we selected 1188 (≥18 years) and 708 (&lt;18 years) genetically-confirmed heterozygous FH, with no missing personal FH features. The prevalence of personal and familial FH features was compared between the two groups. For a sub-group of the paediatric cohort (N = 374), data about premature coronary heart disease (CHD) in second-degree family members were also included in the evaluation. Results: The lower prevalence of typical FH features in children/adolescents vs adults was confirmed: the prevalence of tendon xanthoma was 2.1% vs 13.1%, and arcus cornealis was present in 1.6% vs 11.2% of the cohorts, respectively. No children presented clinical history of premature CHD or cerebral/peripheral vascular disease compared to 8.8% and 5.6% of adults, respectively. The prevalence of premature CHD in first-degree relatives was significantly higher in adults compared to children/adolescents (38.9% vs 19.7%). In the sub-cohort analysis, a premature CHD event in parents was reported in 63 out of 374 subjects (16.8%), but the percentage increased to 54.0% extending the evaluation also to second-degree relatives. Conclusions: In children, the typical FH features are clearly less informative than in adults. A more thorough data collection, adding information about second-degree relatives, could improve the diagnosis of FH at younger age

Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study

Background Familial hypercholesterolemia (FH) is an autosomal dominant disease characterized by elevated plasma levels of LDL-cholesterol that confers an increased risk of premature atherosclerotic cardiovascular disease. Early identification and treatment of FH patients can improve prognosis and reduce the burden of cardiovascular mortality. Aim of this study was to perform the mutational analysis of FH patients identified through a collaboration of 20 Lipid Clinics in Italy (LIPIGEN Study). Methods We recruited 1592 individuals with a clinical diagnosis of definite or probable FH according to the Dutch Lipid Clinic Network criteria. We performed a parallel sequencing of the major candidate genes for monogenic hypercholesterolemia (LDLR, APOB, PCSK9, APOE, LDLRAP1, STAP1). Results A total of 213 variants were detected in 1076 subjects. About 90% of them had a pathogenic or likely pathogenic variants. More than 94% of patients carried pathogenic variants in LDLR gene, 27 of which were novel. Pathogenic variants in APOB and PCSK9 were exceedingly rare. We found 4 true homozygotes and 5 putative compound heterozygotes for pathogenic variants in LDLR gene, as well as 5 double heterozygotes for LDLR/APOB pathogenic variants. Two patients were homozygous for pathogenic variants in LDLRAP1 gene resulting in autosomal recessive hypercholesterolemia. One patient was found to be heterozygous for the ApoE variant p.(Leu167del), known to confer an FH phenotype. Conclusions This study shows the molecular characteristics of the FH patients identified in Italy over the last two years. Full phenotypic characterization of these patients and cascade screening of family members is now in progress

Lipoprotein(a) Genotype Influences the Clinical Diagnosis of Familial Hypercholesterolemia

: Background Evidence suggests that LPA risk genotypes are a possible contributor to the clinical diagnosis of familial hypercholesterolemia (FH). This study aimed at determining the prevalence of LPA risk variants in adult individuals with FH enrolled in the Italian LIPIGEN (Lipid Transport Disorders Italian Genetic Network) study, with (FH/M+) or without (FH/M-) a causative genetic variant. Methods and Results An lp(a) [lipoprotein(a)] genetic score was calculated by summing the number risk-increasing alleles inherited at rs3798220 and rs10455872 variants. Overall, in the 4.6% of 1695 patients with clinically diagnosed FH, the phenotype was not explained by a monogenic or polygenic cause but by genotype associated with high lp(a) levels. Among 765 subjects with FH/M- and 930 subjects with FH/M+, 133 (17.4%) and 95 (10.2%) were characterized by 1 copy of either rs10455872 or rs3798220 or 2 copies of either rs10455872 or rs3798220 (lp(a) score ≥1). Subjects with FH/M- also had lower mean levels of pretreatment low-density lipoprotein cholesterol than individuals with FH/M+ (t test for difference in means between FH/M- and FH/M+ groups &lt;0.0001); however, subjects with FH/M- and lp(a) score ≥1 had higher mean (SD) pretreatment low-density lipoprotein cholesterol levels (223.47 [50.40] mg/dL) compared with subjects with FH/M- and lp(a) score=0 (219.38 [54.54] mg/dL for), although not statistically significant. The adjustment of low-density lipoprotein cholesterol levels based on lp(a) concentration reduced from 68% to 42% the proportion of subjects with low-density lipoprotein cholesterol level ≥190 mg/dL (or from 68% to 50%, considering a more conservative formula). Conclusions Our study supports the importance of measuring lp(a) to perform the diagnosis of FH appropriately and to exclude that the observed phenotype is driven by elevated levels of lp(a) before performing the genetic test for FH

Lipoprotein(a) Genotype Influences the Clinical Diagnosis of Familial Hypercholesterolemia

Background Evidence suggests that LPA risk genotypes are a possible contributor to the clinical diagnosis of familial hypercholesterolemia (FH). This study aimed at determining the prevalence of LPA risk variants in adult individuals with FH enrolled in the Italian LIPIGEN (Lipid Transport Disorders Italian Genetic Network) study, with (FH/M+) or without (FH/M-) a causative genetic variant. Methods and ResultsAn lp(a) [lipoprotein(a)] genetic score was calculated by summing the number risk-increasing alleles inherited at rs3798220 and rs10455872 variants. Overall, in the 4.6% of 1695 patients with clinically diagnosed FH, the phenotype was not explained by a monogenic or polygenic cause but by genotype associated with high lp(a) levels. Among 765 subjects with FH/M- and 930 subjects with FH/M+, 133 (17.4%) and 95 (10.2%) were characterized by 1 copy of either rs10455872 or rs3798220 or 2 copies of either rs10455872 or rs3798220 (lp(a) score &gt;= 1). Subjects with FH/M- also had lower mean levels of pretreatment low-density lipoprotein cholesterol than individuals with FH/M+ (t test for difference in means between FH/M- and FH/M+ groups &lt;0.0001); however, subjects with FH/M- and lp(a) score &gt;= 1 had higher mean (SD) pretreatment low-density lipoprotein cholesterol levels (223.47 [50.40] mg/dL) compared with subjects with FH/M- and lp(a) score=0 (219.38 [54.54] mg/dL for), although not statistically significant. The adjustment of low-density lipoprotein cholesterol levels based on lp(a) concentration reduced from 68% to 42% the proportion of subjects with low-density lipoprotein cholesterol level &gt;= 190 mg/dL (or from 68% to 50%, considering a more conservative formula). ConclusionsOur study supports the importance of measuring lp(a) to perform the diagnosis of FH appropriately and to exclude that the observed phenotype is driven by elevated levels of lp(a) before performing the genetic test for FH

Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial

Aims The objective of the Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT) was to determine whether aliskiren, a direct renin inhibitor, would improve post-discharge outcomes in patients with hospitalization for heart failure (HHF) with reduced ejection fraction. Pre-specified subgroup analyses suggested potential heterogeneity in post-discharge outcomes with aliskiren in patients with and without baseline diabetes mellitus (DM). Methods and results ASTRONAUT included 953 patients without DM (aliskiren 489; placebo 464) and 662 patients with DM (aliskiren 319; placebo 343) (as reported by study investigators). Study endpoints included the first occurrence of cardiovascular death or HHF within 6 and 12 months, all-cause death within 6 and 12 months, and change from baseline in N-terminal pro-B-type natriuretic peptide (NT-proBNP) at 1, 6, and 12 months. Data regarding risk of hyperkalaemia, renal impairment, and hypotension, and changes in additional serum biomarkers were collected. The effect of aliskiren on cardiovascular death or HHF within 6 months (primary endpoint) did not significantly differ by baseline DM status (P = 0.08 for interaction), but reached statistical significance at 12 months (non-DM: HR: 0.80, 95% CI: 0.64-0.99; DM: HR: 1.16, 95% CI: 0.91-1.47; P = 0.03 for interaction). Risk of 12-month all-cause death with aliskiren significantly differed by the presence of baseline DM (non-DM: HR: 0.69, 95% CI: 0.50-0.94; DM: HR: 1.64, 95% CI: 1.15-2.33; P < 0.01 for interaction). Among non-diabetics, aliskiren significantly reduced NT-proBNP through 6 months and plasma troponin I and aldosterone through 12 months, as compared to placebo. Among diabetic patients, aliskiren reduced plasma troponin I and aldosterone relative to placebo through 1 month only. There was a trend towards differing risk of post-baseline potassium ≥6 mmol/L with aliskiren by underlying DM status (non-DM: HR: 1.17, 95% CI: 0.71-1.93; DM: HR: 2.39, 95% CI: 1.30-4.42; P = 0.07 for interaction). Conclusion This pre-specified subgroup analysis from the ASTRONAUT trial generates the hypothesis that the addition of aliskiren to standard HHF therapy in non-diabetic patients is generally well-tolerated and improves post-discharge outcomes and biomarker profiles. In contrast, diabetic patients receiving aliskiren appear to have worse post-discharge outcomes. Future prospective investigations are needed to confirm potential benefits of renin inhibition in a large cohort of HHF patients without D

May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension

Aims Raised blood pressure (BP) is the biggest contributor to mortality and disease burden worldwide and fewer than half of those with hypertension are aware of it. May Measurement Month (MMM) is a global campaign set up in 2017, to raise awareness of high BP and as a pragmatic solution to a lack of formal screening worldwide. The 2018 campaign was expanded, aiming to include more participants and countries. Methods and results Eighty-nine countries participated in MMM 2018. Volunteers (≥18 years) were recruited through opportunistic sampling at a variety of screening sites. Each participant had three BP measurements and completed a questionnaire on demographic, lifestyle, and environmental factors. Hypertension was defined as a systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg, or taking antihypertensive medication. In total, 74.9% of screenees provided three BP readings. Multiple imputation using chained equations was used to impute missing readings. 1 504 963 individuals (mean age 45.3 years; 52.4% female) were screened. After multiple imputation, 502 079 (33.4%) individuals had hypertension, of whom 59.5% were aware of their diagnosis and 55.3% were taking antihypertensive medication. Of those on medication, 60.0% were controlled and of all hypertensives, 33.2% were controlled. We detected 224 285 individuals with untreated hypertension and 111 214 individuals with inadequately treated (systolic BP ≥ 140 mmHg or diastolic BP ≥ 90 mmHg) hypertension. Conclusion May Measurement Month expanded significantly compared with 2017, including more participants in more countries. The campaign identified over 335 000 adults with untreated or inadequately treated hypertension. In the absence of systematic screening programmes, MMM was effective at raising awareness at least among these individuals at risk

Les droits disciplinaires des fonctions publiques : « unification », « harmonisation » ou « distanciation ». A propos de la loi du 26 avril 2016 relative à la déontologie et aux droits et obligations des fonctionnaires

The production of tt‾ , W+bb‾ and W+cc‾ is studied in the forward region of proton–proton collisions collected at a centre-of-mass energy of 8 TeV by the LHCb experiment, corresponding to an integrated luminosity of 1.98±0.02 fb−1 . The W bosons are reconstructed in the decays W→ℓν , where ℓ denotes muon or electron, while the b and c quarks are reconstructed as jets. All measured cross-sections are in agreement with next-to-leading-order Standard Model predictions.The production of $t\overline{t}$, $W+b\overline{b}$ and $W+c\overline{c}$ is studied in the forward region of proton-proton collisions collected at a centre-of-mass energy of 8 TeV by the LHCb experiment, corresponding to an integrated luminosity of 1.98 $\pm$ 0.02 \mbox{fb}^{-1}. The $W$ bosons are reconstructed in the decays $W\rightarrow\ell\nu$, where $\ell$ denotes muon or electron, while the $b$ and $c$ quarks are reconstructed as jets. All measured cross-sections are in agreement with next-to-leading-order Standard Model predictions